One-Time gene injection could end frequent eye shots for wet AMD
Disease control
Completed
This early-stage trial tested a gene therapy called EXG102-031 in 12 people with wet age-related macular degeneration (nAMD), a condition where abnormal blood vessels damage central vision. The therapy was injected into the eye to block these vessels. The main goal was to check s…
Phase: PHASE1 • Sponsor: Exegenesis Bio • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC